Biocryst Pharmaceuticals (BCRX) Total Debt (2011 - 2026)

Biocryst Pharmaceuticals has reported Total Debt for 16 years, with the latest figure at $435.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 24.53% year-over-year to $435.5 million; the trailing twelve-month figure through Mar 2026 stood at $435.5 million (up 24.53% YoY), and the FY2025 full-year result was $38.5 million, down 88.94% from the prior year.
• Total Debt for Q1 2026 stood at $435.5 million, up from $38.5 million in the prior quarter.
• The five-year high for Total Debt was $435.5 million in Q1 2026, with the low at $38.5 million in Q4 2025.
• Historically, Total Debt has averaged $270.4 million across 5 years, with a median of $293.2 million in 2023.
• Annual changes were most pronounced in 2023 — Total Debt soared 102.87% — and 2025, when it sank 88.94%.
• Biocryst Pharmaceuticals' Total Debt stood at $231.6 million in 2022, then surged by 41.09% to $326.8 million in 2023, then climbed by 6.35% to $347.5 million in 2024, then slumped by 88.94% to $38.5 million in 2025, then surged by 1032.53% to $435.5 million in 2026.
• The last three Total Debt figures came in at $435.5 million (Q1 2026), $38.5 million (Q4 2025), and $232.1 million (Q3 2025), per Business Quant data.